Download PDF
Osteologie 2009; 18(01): 35-40
DOI: 10.1055/s-0037-1619880
Osteologie und Labor
Schattauer GmbH

Knochenstoffwechselmarker bei renaler Osteodystrophie

Bone marker and renal osteodystrophy
M. Haas
1   Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse, Medizinische Universität Wien
,
D. Cejka
1   Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse, Medizinische Universität Wien
› Author Affiliations
Further Information

Publication History

eingereicht: 15 January 2009

angenommen: 21 January 2009

Publication Date:
28 December 2017 (online)

    Permissions and Reprints

Zusammenfassung

Die chronische Niereninsuffizienz geht mit einer Störung des Knochenstoffwechsels einher. Diese “renale Osteodystrophie” (ROD) ist im Wesentlichen durch einen beschleunigten oder verlangsamten Knochenumsatz gekennzeichnet. Die Knochenbiopsie ist die genaueste Methode zur Diagnose einer renalen Osteodystrophie, allerdings können auch mittels Messung serologischer Knochenmarker Hinweise auf die zugrundeliegende Form der Erkrankung gefunden werden. Üblicherweise werden zur Abschätzung des Knochenaufbaues Osteokalzin und zur Abschätzung des Knochenabbaues das C-Telopeptid (CTX) bestimmt. Als weiterer effektiver Marker zur Beurteilung der Knochenformation gilt die alkalische Phosphatase. Auch das Parathormon kann zur Beurteilung des Knochenumsatzes herangezogen werden, allerdings ist die Aussagekraft nicht besser als die der anderen Knochenmarker. Nachteilig bei den meisten Knochenmarkern ist ihre renale Elimination. Bei zunehmender Einschränkung der Nierenfunktion kommt es zu einer Kumulation und Verfälschung des tatsächlichen Wertes. Die Bestimmung einzelner Knochenmarker ist daher nicht besonders aussagekräftig und es empfiehlt sich die zeitgleiche Bestimmung mehrerer Marker.

Summary

Chronic renal failure is associated with impaired bone turnover. This so called “renal osteodystrophy” (ROD) is characterized by increased or decreased bone turnover. The diagnostic gold-standard of renal osteodystrophy is the bone biopsy, with subsequent histologic and histomorphometric analyses of the sample. However, also serologic markers might help to elucidate the underlying bone disease. In general, osteocalcin or bone alkaline phosphatase are used as markers of bone formation, and c-telopeptide crosslinks as a marker of bone resorption. Also the serum concentration of the parathyroid hormone can be used to estimate bone turnover. However, the diagnostic reliability of the parathyroid hormone is not superior to that of other serologic bone markers. Most bone markers are excreted by the kidney and cumulate in renal failure. Measurement of only one marker might therefore be misleading. Hence, rather a panel of different markers should be obtained.

Schlüsselwörter

Renale Osteodystrophie - Knochenstoffwechselmarker - Knochenaufbau - Hyperparathyreoidismus - high turnover - low turnover

Keywords

Renal osteodystrophy - bone marker - bone formation - hyperparathyroidism - high turnover - low turnover
 

  • Literatur

  • 1 Barreto DV, Barreto FC, Carvalho AB. et al. Coronary calcification in hemodialysispatients: The contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67: 1576-1582.
    CrossrefPubMedGoogle Scholar
  • 2 Barreto FC, Barreto DV, Moysés RM. et al. K/DOQI – recommended intact PTH levels do not prevent low-trunover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777.
    CrossrefPubMedGoogle Scholar
  • 3 Bervoets A, Spasovski G, Behets G. et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. American Journal of Kidney Diseases 2003; 41: 997-1007.
    CrossrefPubMedGoogle Scholar
  • 4 Bianchi ML, Colantonio G, Montesano A. et al. Bone mass status in different degrees of chronic renal failure. Bone 1992; 13: 225-228.
    CrossrefPubMedGoogle Scholar
  • 5 Cavalier E, Delanaye P, Collette J. et al. Evaluation of different bone markers in hemodialyzed patients. Clinica Chimica Acta 2006; 371: 107-111.
    CrossrefPubMedGoogle Scholar
  • 6 Charhon SA, Delmas PD, Malaval L. et al. Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 1986; 63: 892-897.
    CrossrefPubMedGoogle Scholar
  • 7 Coen G, Ballanti P, Bonucci E. et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302.
    CrossrefPubMedGoogle Scholar
  • 8 Coen G, Ballanti P, Balducci A. et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238.
    PubMedGoogle Scholar
  • 9 Couttenye MM, D’Haese PC, Van Hoof VO. et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072.
    CrossrefPubMedGoogle Scholar
  • 10 Franke S, Lehmann G, Abendroth K. et al. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 1998; 03: 81-88.
    Google Scholar
  • 11 Fried LF, Biggs ML, Shlipak MG. et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007; 18: 282-286.
    CrossrefPubMedGoogle Scholar
  • 12 Gerakis A, Hutchison AJ, Apostolou T. et al. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438.
    CrossrefPubMedGoogle Scholar
  • 13 Haas M, Leko-Mohr Z, Roschger P. et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580-586.
    CrossrefPubMedGoogle Scholar
  • 14 Hamdy NAT, Risteli J, Risteli L. et al. Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis?. Nephrol Dial Transplant 1994; 09: 511-516.
    CrossrefPubMedGoogle Scholar
  • 15 Halleen JM, Tiitinen SL, Ylipahkala H. et al. Tartrate resistant acid phopshtase 5b (TRAP 5b) as a marker of bone resorption. Clin Lab 2006; 52: 499-509.
    PubMedGoogle Scholar
  • 16 Jensen PB, Rasmussen HB, Pedersen FB. Serum concentration of the aminopropeptide of type I procollagen in patients on haemo and peritoneal dialysis. APMIS 1997; 105: 371-377.
    CrossrefPubMedGoogle Scholar
  • 17 Kanis JA, Johnell O, De Laet C. et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002; 17: 1237-1244.
    CrossrefPubMedGoogle Scholar
  • 18 Kraenzlin M, Lau K, Liang L. et al. Development of an immunoassay for human serum osteoclastic tartrate resistant acid phosphatase. J Clin Endocrinol Metab 1990; 71: 442-451.
    CrossrefPubMedGoogle Scholar
  • 19 Lehmann G, Ott U, Kaemmerer D. et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 – 5. Clin Nephrol 2008; 70: 296-305.
    CrossrefPubMedGoogle Scholar
  • 20 Magnusson P, Sharp CA, Magnusson M. et al. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001; 60: 257-265.
    CrossrefPubMedGoogle Scholar
  • 21 Malluche HH, Ritz E, Lange HP. et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 09: 355-362.
    CrossrefPubMedGoogle Scholar
  • 22 Malluche HH, Koszewski N, Monier-Faugere MC. et al. Influence of the parathyroid glands on bone metabolism. Eur J Clin Invest 2006; 36 (Suppl. 02) 23-33.
    CrossrefPubMedGoogle Scholar
  • 23 Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984; 26: 869-874.
    CrossrefPubMedGoogle Scholar
  • 24 Mazzaferro S, Coen G, Ballanti P. et al. Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. Nephron 1990; 56: 261-266.
    CrossrefPubMedGoogle Scholar
  • 25 Mazzaferro S, Pasquali M, Ballanti P. et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10: 52-58.
    CrossrefPubMedGoogle Scholar
  • 26 Montagnani A, Gonelli S, Cepollaro C. et al. A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur J Int Med 2003; 14: 172-177.
    CrossrefPubMedGoogle Scholar
  • 27 Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17: 3223-3332.
    CrossrefPubMedGoogle Scholar
  • 28 Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008; 74: 721-731.
    CrossrefPubMedGoogle Scholar
  • 29 Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-883.
    CrossrefPubMedGoogle Scholar
  • 30 Qi Q, Maunier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
    CrossrefPubMedGoogle Scholar
  • 31 Rix M, Andreassen H, Eskildsen P. et al. Bone mineral density and biochemical markers of bone trunover in patients with predialysis chronic renal failure. Kidney International 1999; 56: 1084-1093.
    CrossrefPubMedGoogle Scholar
  • 32 Ueda M, Inaba M, Okuno S. et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. American Journal of Kidney Diseases 2002; 40: 802-809.
    CrossrefPubMedGoogle Scholar
  • 33 Urena P, Hruby M, Ferreira A. et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 07: 506-512.
    Google Scholar
  • 34 Urena P, Ferreira A, Kung VT. et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 1995; 10: 932-939.
    PubMedGoogle Scholar
  • 35 Vega D, Maalouf NM, Sakhaee K. The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. J Clin Endocrinol Metab 2007; 92: 4514-4521.
    CrossrefPubMedGoogle Scholar
  • 36 Wang M, Hercz G, Sherrard D. et al. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844.
    CrossrefPubMedGoogle Scholar